Jonah Feldman

Articles

Palbociclib Plus Anti-HER2 and Endocrine Therapy Prolongs PFS in HR+/HER2+ Breast Cancer

December 12th 2024

Palbociclib plus anti-HER2 and endocrine therapy improved progression-free survival in hormone receptor–positive, HER2-positive metastatic breast cancer.

Risk Management Measures Improved Safety, Prevention, and Management of Ponatinib-Associated AEs in CML and AML

December 11th 2024

Select safety measures have improved the prevention and management of risks associated with ponatinib in ALL and CML over 10 years.

Ide-Cel Shows Real-World Efficacy in CNS Multiple Myeloma

December 10th 2024

Real-world data showed ide-cel was active in patients with central nervous system manifestations of multiple myeloma.

Zanubrutinib Reduces Long-Term Risk of Progression or Death by 71% in Newly Diagnosed CLL/SLL

December 9th 2024

Frontline treatment with zanubrutinib continued to improve PFS vs bendamustine plus rituximab at 5 years in patients with treatment-naive CLL/SLL.

Pelabresib Plus Ruxolitinib Leads to Sustained Responses in JAK Inhibitor–Naive Myelofibrosis

December 9th 2024

Improvements in the 4 hallmarks of myelofibrosis were observed with pelabresib plus ruxolitinib vs placebo plus ruxolitinib in JAK inhibitor-naive disease.

Isa-KRd Induction Therapy Elicits Responses, MRD Negativity in Transplant-Eligible, Newly Diagnosed Myeloma

September 27th 2024

Patients with newly diagnosed, transplant-eligible multiple myeloma achieved deep responses and MRD negativity with isa-KRd induction therapy.

Radium-223 Before Docetaxel Demonstrates Better QOL in mCRPC, With No Difference in Survival

September 27th 2024

Radium-223 prior to docetaxel improved quality of life and tolerability in patients with metastatic castration-resistant prostate cancer according to data from the RAPSON trial.

Darolutamide Plus ADT Improves rPFS in mHSPC

September 16th 2024

Darolutamide plus ADT shows PFS benefit without docetaxel in metastatic hormone-sensitive prostate cancer.

T-DXd Delays Time to Deterioration in Functioning, Pain in HR+, HER2-Low and -Ultralow Metastatic Breast Cancer

September 15th 2024

T-DXd improved time to deterioration for pain and other subscores, with no decline in overall QOL in HER2 low/ultralow breast cancer.

RP1 Plus Nivolumab Demonstrates Durable Antitumor Activity in Advanced Melanoma

September 15th 2024

RP1 plus nivolumab offers durable responses and a favorable safety profile for patients with melanoma after progression on anti–PD-1 therapy.

ARV-766 Demonstrates Clinical Activity in AR LBD–Mutated Metastatic CRPC

June 10th 2024

The investigational PROTAC AR degrader ARV-766 showed promising clinical activity and tolerability in patients with metastatic castration-resistant prostate cancer.

Study Evaluates Synergistic Potential of Nab-Sirolimus Plus Letrozole in Advanced/Recurrent Endometrial Cancer

March 17th 2024

The activity of nab-sirolimus plus letrozole is under study in patients with advanced or recurrent endometrioid endometrial cancer.

Later-Line Ruxolitinib Use Produces Ongoing Benefit in Real-World Patients With cGVHD

February 25th 2024

Real-world ruxolitinib use in chronic GVHD was primarily in the second- or third-line, lasted for a median of 8 months, and involved dose adjustments.

Immune Engager Therapies Demonstrate Promise Following Relapse on Ide-Cel in Multiple Myeloma

February 23rd 2024

Treatment with immune engager therapies following relapse on ide-cel resulted in better median PFS vs other therapies for patients with multiple myeloma.

Post-Hoc Analysis of ARASENS Reinforces Use of Darolutamide/ADT/Docetaxel Combo as SOC in mHSPC

January 25th 2024

A post-hoc analysis of censored patients with mHSPC showed benefit with darolutamide, ADT, and docetaxel, supporting primary data from the ARASENS trial.

Obe-Cel Elicits High Remission Rates in R/R B-ALL Irrespective of Leukemic Burden

December 10th 2023

Obecabtagene autoleucel elicited durable responses in patients with relapsed or refractory B-cell acute lymphoblastic leukemia independent of leukemic burden at lymphodepletion, although better outcomes were observed in those with lower burden.

Lenvatinib/Pembrolizumab/Chemo Is Safe With Early Efficacy Signals in mESCC

October 23rd 2023

The combination of lenvatinib, pembrolizumab, and chemotherapy had a manageable safety profile and elicited preliminary antitumor activity in patients with metastatic esophageal squamous cell carcinoma.

Durcabtagene Autoleucel Demonstrates Rapid Proliferation and Persistence in Relapsed/Refractory Myeloma

September 28th 2023

Use of the novel T-charge rapid manufacturing platform for the production of durcabtagene autoleucel CAR T cells within 2 days was successful in producing rapid and robust in vivo expansion, as well as long-term T-cell persistence in patients with relapsed/refractory multiple myeloma, according to a correlative analysis of data from an ongoing phase 1 trial presented at the 2023 IMS Annual Meeting.

Iflinatamab Deruxtecan Elicits Clinical Activity in SCLC

September 10th 2023

Treatment with the antibody-drug conjugate ifinatamab deruxtecan in heavily pretreated patients with small cell lung cancer led to promising efficacy and a manageable safety profile.

Fianlimab/Cemiplimab Demonstrates Early Clinical Activity and Safety in Advanced Melanoma

June 6th 2023

The LAG-3 inhibitor fianlimab plus cemiplimab produced high and consistent tumor responses and a comparable toxicity profile to that of anti–PD-L1 monotherapies in patients with advanced melanoma who were PD-L1 inhibitor–naïve in the advanced setting, according to data from a phase 1 study.